Peptide news
Curated weekly from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical takeaways for users, not academic abstracts.
- Regulatorynews.google.com
FDA Expert Panel Backs Compounding of Six Peptides
An FDA expert panel backed the compounding of six peptides, but the title does not identify the compounds or confirm a final FDA decision. If you use compounded peptides, watch for the FDA’s final ruling and verify that your specific peptide is included.
Read source → - Regulatorythefdalawblog.com
The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List
FDA’s PCAC added two more bulk drug substances to the 503A list, continuing its recent peptide related compounding decisions. If you use compounded peptides, ask your prescriber or pharmacy whether your specific substance is now on the 503A list before ordering.
Read source → - Regulatorynews.google.com
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
An FDA advisory panel narrowly opposed compounding one peptide while supporting two others, but the agency will make the final call. If you use a compounded peptide, watch for FDA’s decision and ask your pharmacy whether your product is affected.
Read source → - Regulatorynews.google.com
FDA advisers back first four of seven unapproved peptides under review for looser rules
FDA advisers backed the first four of seven unapproved peptides being reviewed for looser rules. If you use an unapproved peptide, watch for the FDA’s final decisions before changing what you buy or use.
Read source → - Regulatorythefdalawblog.com
PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List
PCAC approved four bulk drug substances for the 503A list, potentially expanding what eligible compounding pharmacies can prepare. If you use compounded peptides, watch for FDA confirmation of the final list before assuming these substances are available.
Read source → - Regulatorynews.google.com
UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm
An FDA compounding advisory committee favored peptides on the first day of its closely watched review, but the title does not identify which products or recommendations were discussed. If you use compounded peptides, watch for the FDA’s final decisions before changing your sourcing or treatment plan.
Read source → - Regulatorynews.google.com
In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
An FDA advisory panel narrowly voted to allow compounding of unapproved peptides, a policy win for RFK Jr. If you use compounded peptides, watch for the FDA’s final decision and verify that your compounder follows current FDA rules before ordering.
Read source → - Trialslilly.gcs-web.com
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Retatrutide met its primary endpoint in two Phase 3 obesity trials. At 80 weeks, participants lost up to an average of 49.6 pounds, or 20.8%, with type 2 diabetes, and 55.8 pounds, or 22.6%, with severe obesity and cardiovascular disease. If you are considering retatrutide, watch for Lilly’s planned FDA filing in Q1 2027 and remember that it remains investigational.
Read source → - Regulatorynews.google.com
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
An FDA advisory panel is weighing access to seven popular peptides this week, which could affect how you obtain them. If you use a popular peptide, watch the panel’s recommendations and confirm any access changes with your provider.
Read source → - Regulatorynews.google.com
Hims & Hers stands to gain if the FDA loosens restrictions on peptides
Hims & Hers could gain if the FDA loosens current peptide restrictions, potentially expanding what it can offer through its platform. If you use its services, watch FDA policy changes and confirm that any new peptide offering is legally available and properly sourced.
Read source → - Trialsnews.google.com
Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials
Retatrutide met Phase 3 weight loss endpoints in 2 obesity trials. If you are considering retatrutide, watch for full trial data and regulatory decisions before changing your peptide plan.
Read source → - Regulatorynews.google.com
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
Lilly says new data support seeking FDA approval for the obesity drug retatrutide. If you are considering retatrutide, watch for the FDA filing and review the supporting data before changing your treatment plan.
Read source →
Pepdex aggregates research news from primary sources only, FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted outlets (BioPharma Dive, STAT, AJMC, university research pages). We summarize in plain English; you click the source link to verify. No vendor sponsorship.